PEMIGATINIB FOR PAN-CANCER PATIENTS WITH FGF/FGFR-POSITIVE ADVANCED MALIGNANCIES
This phase I/II trial evaluated the safety, activity, and efficacy of pemigatinib, a selective FGFR 1–3 inhibitor, in patients with refractory advanced malignancies, with or without FGF and FGFR gene alterations. Pemigatinib demonstrated a favorable safety profile and pharmacologic/clinical activity in a variety of solid tumor types, including cholangiocarcinoma, urothelial carcinoma, recurrent pilocytic astrocytoma and […]
PEMIGATINIB FOR PAN-CANCER PATIENTS WITH FGF/FGFR-POSITIVE ADVANCED MALIGNANCIES Read More »
